25-hydroxyvitamin D3 status is associated with developing adaptive and innate immune responses in the first 6 months of life

A.P. Jones, Nina D'Vaz, Suzanne Meldrum, Debbie Palmer, Brad Zhang, Susan Prescott

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Vitamin D (25[OH]D3) status in early life has been linked to the risk of allergic disease in multiple observational studies. While immunomodulating properties are well recognized, there are few longitudinal studies of 25(OH)D3 status, immune function and allergic disease in infants.

Objective: To investigate 25(OH)D3 levels at birth [cord blood (CB)] and at 6 months of age in relation to immune function at 6 months of age, and clinical outcomes up to 30 months of age in infants with a maternal history of atopy.

Methods: In a subset of infants (n = 225) enrolled in a RCT (ACTRN12606000281594), 25(OH)D3 levels were assessed in relation to peripheral blood mononuclear cell cytokine responses to house dust mite (HDM), ovalbumin (OVA) and β-lactoglobulin allergens, or Toll-like receptor (TLR) ligands (lipopolysaccharide, lipoteichoic acid, polyinosinic : polycytidylic acid and CpG oligonucleotide) at 6 months of age, in addition to clinical outcomes (eczema, wheeze and allergen sensitisation) up to 30 months of age.

Results: Infants with higher 25(OH)D3 at birth (≥ 75 nmol/L, compared with <50 nmol/L) had lower IL-5 and IL-13 responses to HDM by 6 months (P <0.001 and P = 0.003, respectively). This was also reflected in strong inverse correlations between CB 25(OH)D3 levels and HDM IL-13 (ρ = -0.57; P = 0.0002) and IL-5 (ρ = -0.59, P = 0.0001) responses, with a similar trend for IL-5 (ρ = -0.29; P = 0.009) responses to OVA. For innate stimulations, higher 25(OH)D3 levels at 6 months were associated with greater responses to TLR ligands. Additionally, higher CB 25(OH)D3 was associated with reduced risk eczema at 6 months (P = 0.011) and 12 months (P = 0.034).

Conclusion: This suggests that improving 25(OH)D3 status in pregnancy or early infancy may reduce the development of allergic disease in high-risk infants by inhibiting cytokine profiles associated with allergy. Results of clinical trials are awaited to determine the efficacy of vitamin D supplementation in allergy prevention.

© 2014 John Wiley & Sons Ltd

Original languageEnglish
Pages (from-to)220-231
JournalClinical and Experimental Allergy
Volume45
Issue number1
DOIs
Publication statusPublished - Jan 2015

Fingerprint

Calcifediol
Adaptive Immunity
Innate Immunity
Pyroglyphidae
Interleukin-5
Fetal Blood
Interleukin-13
Toll-Like Receptors
Eczema
Ovalbumin
Vitamin D
Allergens
Hypersensitivity
Parturition
Cytokines
Ligands
Poly I-C
Lactoglobulins
Nuclear Family
Oligonucleotides

Cite this

@article{9e5799395a1c456aa9d5acc96c61ee06,
title = "25-hydroxyvitamin D3 status is associated with developing adaptive and innate immune responses in the first 6 months of life",
abstract = "Background: Vitamin D (25[OH]D3) status in early life has been linked to the risk of allergic disease in multiple observational studies. While immunomodulating properties are well recognized, there are few longitudinal studies of 25(OH)D3 status, immune function and allergic disease in infants. Objective: To investigate 25(OH)D3 levels at birth [cord blood (CB)] and at 6 months of age in relation to immune function at 6 months of age, and clinical outcomes up to 30 months of age in infants with a maternal history of atopy. Methods: In a subset of infants (n = 225) enrolled in a RCT (ACTRN12606000281594), 25(OH)D3 levels were assessed in relation to peripheral blood mononuclear cell cytokine responses to house dust mite (HDM), ovalbumin (OVA) and β-lactoglobulin allergens, or Toll-like receptor (TLR) ligands (lipopolysaccharide, lipoteichoic acid, polyinosinic : polycytidylic acid and CpG oligonucleotide) at 6 months of age, in addition to clinical outcomes (eczema, wheeze and allergen sensitisation) up to 30 months of age. Results: Infants with higher 25(OH)D3 at birth (≥ 75 nmol/L, compared with <50 nmol/L) had lower IL-5 and IL-13 responses to HDM by 6 months (P <0.001 and P = 0.003, respectively). This was also reflected in strong inverse correlations between CB 25(OH)D3 levels and HDM IL-13 (ρ = -0.57; P = 0.0002) and IL-5 (ρ = -0.59, P = 0.0001) responses, with a similar trend for IL-5 (ρ = -0.29; P = 0.009) responses to OVA. For innate stimulations, higher 25(OH)D3 levels at 6 months were associated with greater responses to TLR ligands. Additionally, higher CB 25(OH)D3 was associated with reduced risk eczema at 6 months (P = 0.011) and 12 months (P = 0.034). Conclusion: This suggests that improving 25(OH)D3 status in pregnancy or early infancy may reduce the development of allergic disease in high-risk infants by inhibiting cytokine profiles associated with allergy. Results of clinical trials are awaited to determine the efficacy of vitamin D supplementation in allergy prevention. {\circledC} 2014 John Wiley & Sons Ltd",
author = "A.P. Jones and Nina D'Vaz and Suzanne Meldrum and Debbie Palmer and Brad Zhang and Susan Prescott",
year = "2015",
month = "1",
doi = "10.1111/cea.12449",
language = "English",
volume = "45",
pages = "220--231",
journal = "Clinical & Experimental Allergy",
issn = "0954-7894",
publisher = "Wiley Blackwell",
number = "1",

}

25-hydroxyvitamin D3 status is associated with developing adaptive and innate immune responses in the first 6 months of life. / Jones, A.P.; D'Vaz, Nina; Meldrum, Suzanne; Palmer, Debbie; Zhang, Brad; Prescott, Susan.

In: Clinical and Experimental Allergy, Vol. 45, No. 1, 01.2015, p. 220-231.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 25-hydroxyvitamin D3 status is associated with developing adaptive and innate immune responses in the first 6 months of life

AU - Jones, A.P.

AU - D'Vaz, Nina

AU - Meldrum, Suzanne

AU - Palmer, Debbie

AU - Zhang, Brad

AU - Prescott, Susan

PY - 2015/1

Y1 - 2015/1

N2 - Background: Vitamin D (25[OH]D3) status in early life has been linked to the risk of allergic disease in multiple observational studies. While immunomodulating properties are well recognized, there are few longitudinal studies of 25(OH)D3 status, immune function and allergic disease in infants. Objective: To investigate 25(OH)D3 levels at birth [cord blood (CB)] and at 6 months of age in relation to immune function at 6 months of age, and clinical outcomes up to 30 months of age in infants with a maternal history of atopy. Methods: In a subset of infants (n = 225) enrolled in a RCT (ACTRN12606000281594), 25(OH)D3 levels were assessed in relation to peripheral blood mononuclear cell cytokine responses to house dust mite (HDM), ovalbumin (OVA) and β-lactoglobulin allergens, or Toll-like receptor (TLR) ligands (lipopolysaccharide, lipoteichoic acid, polyinosinic : polycytidylic acid and CpG oligonucleotide) at 6 months of age, in addition to clinical outcomes (eczema, wheeze and allergen sensitisation) up to 30 months of age. Results: Infants with higher 25(OH)D3 at birth (≥ 75 nmol/L, compared with <50 nmol/L) had lower IL-5 and IL-13 responses to HDM by 6 months (P <0.001 and P = 0.003, respectively). This was also reflected in strong inverse correlations between CB 25(OH)D3 levels and HDM IL-13 (ρ = -0.57; P = 0.0002) and IL-5 (ρ = -0.59, P = 0.0001) responses, with a similar trend for IL-5 (ρ = -0.29; P = 0.009) responses to OVA. For innate stimulations, higher 25(OH)D3 levels at 6 months were associated with greater responses to TLR ligands. Additionally, higher CB 25(OH)D3 was associated with reduced risk eczema at 6 months (P = 0.011) and 12 months (P = 0.034). Conclusion: This suggests that improving 25(OH)D3 status in pregnancy or early infancy may reduce the development of allergic disease in high-risk infants by inhibiting cytokine profiles associated with allergy. Results of clinical trials are awaited to determine the efficacy of vitamin D supplementation in allergy prevention. © 2014 John Wiley & Sons Ltd

AB - Background: Vitamin D (25[OH]D3) status in early life has been linked to the risk of allergic disease in multiple observational studies. While immunomodulating properties are well recognized, there are few longitudinal studies of 25(OH)D3 status, immune function and allergic disease in infants. Objective: To investigate 25(OH)D3 levels at birth [cord blood (CB)] and at 6 months of age in relation to immune function at 6 months of age, and clinical outcomes up to 30 months of age in infants with a maternal history of atopy. Methods: In a subset of infants (n = 225) enrolled in a RCT (ACTRN12606000281594), 25(OH)D3 levels were assessed in relation to peripheral blood mononuclear cell cytokine responses to house dust mite (HDM), ovalbumin (OVA) and β-lactoglobulin allergens, or Toll-like receptor (TLR) ligands (lipopolysaccharide, lipoteichoic acid, polyinosinic : polycytidylic acid and CpG oligonucleotide) at 6 months of age, in addition to clinical outcomes (eczema, wheeze and allergen sensitisation) up to 30 months of age. Results: Infants with higher 25(OH)D3 at birth (≥ 75 nmol/L, compared with <50 nmol/L) had lower IL-5 and IL-13 responses to HDM by 6 months (P <0.001 and P = 0.003, respectively). This was also reflected in strong inverse correlations between CB 25(OH)D3 levels and HDM IL-13 (ρ = -0.57; P = 0.0002) and IL-5 (ρ = -0.59, P = 0.0001) responses, with a similar trend for IL-5 (ρ = -0.29; P = 0.009) responses to OVA. For innate stimulations, higher 25(OH)D3 levels at 6 months were associated with greater responses to TLR ligands. Additionally, higher CB 25(OH)D3 was associated with reduced risk eczema at 6 months (P = 0.011) and 12 months (P = 0.034). Conclusion: This suggests that improving 25(OH)D3 status in pregnancy or early infancy may reduce the development of allergic disease in high-risk infants by inhibiting cytokine profiles associated with allergy. Results of clinical trials are awaited to determine the efficacy of vitamin D supplementation in allergy prevention. © 2014 John Wiley & Sons Ltd

U2 - 10.1111/cea.12449

DO - 10.1111/cea.12449

M3 - Article

VL - 45

SP - 220

EP - 231

JO - Clinical & Experimental Allergy

JF - Clinical & Experimental Allergy

SN - 0954-7894

IS - 1

ER -